We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

146 hedge funds and large institutions have $491M invested in Castle Biosciences in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 72 increasing their positions, 29 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 29

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

3.85% less ownership

Funds ownership: 89.76% → 85.91% (-3.9%)

9% less funds holding

Funds holding: 160 → 146 (-14)

31% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 36

50% less capital invested

Capital invested by funds: $988M → $491M (-$498M)

Holders
146
Holders Change
-14
Holders Change %
-8.75%
% of All Funds
2.46%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
25
Increased
72
Reduced
29
Closed
36
Calls
$645K
Puts
–
Net Calls
+$645K
Net Calls Change
+$173K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$14.6M
2
Citadel Advisors
Citadel Advisors
Florida
+$10.3M
3
GF
Greenhouse Funds
Maryland
+$10.2M
4
RI
RTW Investments
New York
+$9.69M
5
BG
Bellevue Group
Switzerland
+$7.75M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$28M
2
AIM
ARK Investment Management
Florida
-$27.2M
3
GPGA
Grandeur Peak Global Advisors
Utah
-$24.4M
4
NCGI
Next Century Growth Investors
Minnesota
-$24.2M
5
PM
Pembroke Management
Quebec, Canada
-$20.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$4.22M +$1.62M +69,700 +57%
Charles Schwab
27
Charles Schwab
California
$3.75M +$115K +4,928 +3%
SSA
28
Schonfeld Strategic Advisors
New York
$3.68M +$2.46M +106,059 +172%
TFS
29
TrustCore Financial Services
Tennessee
$3.62M – – –
Ameriprise
30
Ameriprise
Minnesota
$3.52M +$850K +36,586 +30%
UBS AM
31
UBS AM
Illinois
$3.45M -$481K -20,679 -12%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$3.41M +$3.06M +131,500 +553%
PCM
33
Portolan Capital Management
Massachusetts
$3.4M +$3.6M +154,968 New
Two Sigma Investments
34
Two Sigma Investments
New York
$3.28M +$3.47M +149,429 New
CSS
35
Cubist Systematic Strategies
Connecticut
$3.01M +$2.38M +102,397 +294%
VOYA Investment Management
36
VOYA Investment Management
Georgia
$2.96M +$2.81M +121,100 +878%
MPAM
37
Monarch Partners Asset Management
Massachusetts
$2.92M -$545K -23,460 -15%
Citigroup
38
Citigroup
New York
$2.92M +$2.89M +124,294 +1,438%
Goldman Sachs
39
Goldman Sachs
New York
$2.63M +$1.31M +56,463 +89%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$2.56M +$2.71M +116,617 New
N
41
Nuveen
North Carolina
$2.47M +$950K +40,888 +57%
EGM
42
Engineers Gate Manager
New York
$2.39M +$2.53M +108,940 New
Morgan Stanley
43
Morgan Stanley
New York
$2.39M +$1.9M +81,797 +301%
SEI Investments
44
SEI Investments
Pennsylvania
$2.33M +$2.47M +106,384 New
Ohio Public Employees Retirement System (OPERS)
45
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.94M – – –
Squarepoint
46
Squarepoint
New York
$1.79M +$1.65M +71,074 +687%
GCM
47
Graham Capital Management
Connecticut
$1.62M +$1.71M +73,672 New
Bank of New York Mellon
48
Bank of New York Mellon
New York
$1.56M -$712K -30,648 -30%
PFM
49
Premier Fund Managers
United Kingdom
$1.2M – – –
IP
50
Isthmus Partners
Wisconsin
$1.16M +$290K +12,491 +31%
1
2
3 4 5

CSTL Hedge Fund Activity: Q2 2022 in Review

146 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2022, worth a combined $491M — down 50% from $988M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CSTL and 25 opened new positions — a net loss of 11 holders — while 29 trimmed existing stakes and 72 added.

The largest buyer was Millennium Management, adding an estimated $14.6M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $28M sold.

  • 146 institutional investors held Castle Biosciences (CSTL) as of Q2 2022, down from 160 in Q1 2022.
  • Funds reported $491M of Castle Biosciences stock for Q2 2022, down 50% quarter-over-quarter.
  • 25 funds opened new Castle Biosciences positions in Q2 2022 and 36 closed out, a net change of -11 holders.
  • The largest Castle Biosciences buyer in Q2 2022 was Millennium Management, an estimated $14.6M added.
  • The largest Castle Biosciences seller in Q2 2022 was Point72 Asset Management, an estimated $28M sold.

Based on aggregated 13F filings for Q2 2022.